Anna Świeboda-Sadlej

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka et al. · Annals of Oncology · 2015 · 163 citations · Full text

Oncology, Pancreatic Cancer, Clinical Trials +8

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

Alfredo Carrato, Anna Świeboda-Sadlej, Marzanna Staszewska-Skurczyńska et al. · Journal of Clinical Oncology · 2013 · 132 citations · Full text

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer

Eric Van Cutsem, Cathy Eng, Elżbieta Nowara et al. · Clinical Cancer Research · 2014 · 107 citations · Full text

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

Martin Eatock, Niall C. Tebbutt, Carolyn Bampton et al. · Annals of Oncology · 2012 · 64 citations · Full text

Oncology, Phase Ii, Gastrointestinal Oncology +8

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) <i>KRAS</i> metastatic colorectal cancer (mCRC): Primary and biomarker analyses.

Cathy Eng, Eric Van Cutsem, Elżbieta Nowara et al. · Journal of Clinical Oncology · 2011 · 37 citations

Amg 102, Ib/ii Trial, Human Growth +25